Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2R�� binding, in patients with advanced solid tumors.

Citation

• Vasselli, J. R., Frentzas, S., Weickhardt, A. J., de Souza, P. L., Tang, J., Wyant, T., . . . Knickerbocker, A. (2022). Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2R�� binding, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), tps2671. doi:10.1200/jco.2022.40.16_suppl.tps2671

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.tps2671

Web Of Science Accession Number

Start Page

• tps2671

End Page

• tps2671

Volume

• 40

Issue

• 16_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2022

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Vasselli, J. R., Frentzas, S., Weickhardt, A. J., de Souza, P. L., Tang, J., Wyant, T., . . . Knickerbocker, A. (2022). Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2R�� binding, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), tps2671. doi:10.1200/jco.2022.40.16_suppl.tps2671

Digital Object Identifier (doi)

• 10.1200/jco.2022.40.16_suppl.tps2671

Web Of Science Accession Number

Start Page

• tps2671

End Page

• tps2671

Volume

• 40

Issue

• 16_suppl

Place Of Publication